For the year ending 2025-12-31, ADMA had -$15,517K decrease in cash & cash equivalents over the period. $27,821K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net income (loss) | 146,930 |
| Depreciation and amortization | 8,096 |
| Loss on disposal of fixed assets | -9 |
| Deferred income tax provision | -11,020 |
| Interest paid in kind | 0 |
| Stock-based compensation | 20,026 |
| Amortization of debt discount | 717 |
| Loss on extinguishment of debt | -3,336 |
| Amortization of license revenue | -143 |
| Accounts receivable | 108,430 |
| Inventories | 36,230 |
| Prepaid expenses and other current assets | 1,525 |
| Deposits and other assets | -279 |
| Accounts payable | 2,330 |
| Accrued expenses | 5,212 |
| Other current and non-current liabilities | -1,231 |
| Net cash provided by operating activities | 50,396 |
| Purchase of property and equipment | 22,575 |
| Acquisition of intangible assets | 316 |
| Deposit received on net assets held for sale | 1,000 |
| Net cash used in investing activities | -21,891 |
| Term loan payments-Ares Credit Facility | 32,500 |
| Ares revolving facility payments-Ares Credit Facility | 72,500 |
| Ares revolving facility proceeds-Ares Credit Facility | 30,000 |
| Term loan payments-JPMCredit Facilities | 938 |
| Jpm term loan proceeds-JPMCredit Facilities | 75,000 |
| Prepayment penalties on repayment of debt | 1,031 |
| Proceeds from issuance of note payable | 0 |
| Taxes paid on vested restricted stock units | 9,547 |
| Payments on finance lease obligations | 0 |
| Debt issuance costs | 2,237 |
| Net proceeds from the exercise of stock options | 2,984 |
| Payment of end of term fee | 1,313 |
| Payment of deferred financing fees | 0 |
| Acquisition of treasury stock | 31,940 |
| Net cash used in financing activities | -44,022 |
| Net (decrease) increase in cash and cash equivalents | -15,517 |
| Cash and cash equivalents - beginning of year | 103,147 |
| Cash and cash equivalents - end of year | 87,630 |
ADMA BIOLOGICS, INC. (ADMA)
ADMA BIOLOGICS, INC. (ADMA)